article thumbnail

Key developments in pharmaceutical manufacturing – September 2023

European Pharmaceutical Review

September 2023 saw a wave of new pharmaceutical manufacturing facility expansions and launches across Europe. Research by the Confederation of British Industry (CBI) , released in September this year, highlighted progress for UK manufacturing in its latest Industrial Trends Survey. Meath opened last month.

article thumbnail

Eli Lilly promises additional $1.6b manufacturing investment

European Pharmaceutical Review

billion and another 200 new jobs is planned for Eli Lilly and Company’s two new pharmaceutical manufacturing sites in Boone County, US. Eli Lilly’s investment here is the largest manufacturing investment at a single location in its history. Students will also be able to access a smart manufacturing lab.

article thumbnail

Methods for strain comparison and differentiation of environmental isolates

European Pharmaceutical Review

NCIMB Ltd provides microbial identification services and curates The National Collection of Industrial, Food and Marine Bacteria – one of the culture collections that makes up the UK Biological Resource Centre Network.

article thumbnail

European authorities recognised for leading medicine regulatory oversight

European Pharmaceutical Review

WHO confirmed that the newly approved WLAs include: The European Medicines Regulatory Network (EMRN), which is made up of the European Commission (EC), the European Medicines Agency (EMA) and the medicines regulatory authorities of 30 countries.

article thumbnail

Improving upstream fermentation with end-to-end automation

European Pharmaceutical Review

This process is representative of common microbial fermentation in the pharmaceutical industry, according to the authors. However, microbial-based fermentation results in numerous different challenges for in-line spectroscopy-based PAT, Reid et al. highlighted.

article thumbnail

Call to arms as UK falls back in medicines manufacturing

pharmaphorum

The LSIMF was announced within an overall investment of £354 million for life sciences manufacturing, said MMIP, which added it will be “important to understand how and when the remaining £294 million will be allocated.” ” Image from the Association of the British Pharmaceutical Industry (ABPI).

article thumbnail

Tackling fake pharmaceuticals: an industry united against counterfeit products

European Pharmaceutical Review

Consequently, pharmaceutical manufacturers risk their reputation if impersonating products fail to deliver the expected quality or health impact. Criminal networks are penetrating established digital and ecommerce channels, benefitting from their trusted authenticity and authority to distribute fake products to unsuspecting patients.